Scarica l'app Stockscreener
5.56
5.10%
0.27
Dopo l'orario di chiusura:
5.63
0.07
+1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$5.29
Aprire:
$5.2
Volume 24 ore:
292.64K
Relative Volume:
1.11
Capitalizzazione di mercato:
$40.09M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.2158
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
+28.70%
1M Prestazione:
-67.81%
6M Prestazione:
-51.99%
1 anno Prestazione:
-24.56%
Intervallo 1D:
$5.20
$5.68
Intervallo di 1 settimana:
$4.20
$5.68
Portata 52W:
$4.20
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
5.56 | 38.14M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Price-Driven Insight from (ATRA) for Rule-Based Strategy - Stock Traders Daily
Short Squeeze: Can Atara Biotherapeutics Inc weather a recessionJuly 2025 WrapUp & Low Drawdown Trading Techniques - baoquankhu1.vn
Patterns Watch: Can Atara Biotherapeutics Inc weather a recessionMarket Sentiment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - FinancialContent
What momentum indicators show for Atara Biotherapeutics Inc. stockMarket Rumors and News & Trusted Financial Advisors at No Cost - bollywoodhelpline.com
FDA Again Rejects Atara - labusinessjournal.com
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock - Defense World
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com Australia
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57% - Intellectia AI
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com Canada
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form - TipRanks
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com
FDA says no to rare transplant cancer treatment patients awaited - Stock Titan
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Shares Down 21.6%What's Next? - MarketBeat
Why Atara Biotherapeutics Inc. stock could be next big winnerJuly 2025 Sentiment & Weekly High Conviction Ideas - Улправда
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - Улправда
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - Улправда
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):